Researchers conducted a study to determine the association between the detection of bacteria in the upper respiratory tract and the risk for acute lower respiratory tract infection in young children.
In this fifth update to the living guidelines on drugs for the treatment of COVID-19, the World Health Organization analyzed results of clinical trials that assessed the effects of casirivimab-imdevimab and corticosteroids in patients with severe and non-severe disease.
Investigators conducted a study that compared outcomes between patients with COVID-19 infected with the Alpha, Beta, or Delta variants and those infected with wild-type virus.
Bacterial superinfection at time of intubation occurred in <25 percent of patients; reduced antibiotic use seen with bronchoalveolar lavage-based management versus current guidelines.
Risk slightly higher after introduction of nationwide pneumococcal conjugate vaccine.
The study found prenatal exposure to carbon monoxide in household air pollution was a risk factor for early pneumonia, a leading global cause of death for children younger than 5 years.
Pneumonia prevention interventions such as proper oral care, head-of-bed elevation, and incentive spirometry, are not being provided to most patients outside the ICU, leading to greater than two-thirds of hospital-acquired pneumonia.
Researchers assessed the performance of a pneumonia panel in relation to clinical measures and outcome variables.
The recall was initiated because the product had prolonged exposure to extremely cold weather during shipment.
Children with neurologic comorbidities undergoing surgery have an elevated risk for pneumonia within 30 days after surgery.
